Loading…
Clinical-stage biotech developing tinlarebant, an oral drug to slow vision loss in inherited and age-related retinal diseases.
Clinical-stage biotech developing tinlarebant, an oral drug to slow vision loss in inherited and age-related retinal diseases.
Has no product to sell, so its costs are paid from investor money raised in share sales. Its value hinges on late-stage trial results for tinlarebant and on regulatory approvals.
Moat: none (IP / patents). Pre-commercial; edge rests on being an oral alternative to injectable treatments for retinal disease.
Headquarters: San Diego, California, United States · Founded: 2018 · Employees: 41
Size Belite Bio, Inc. ADR (BLTE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $6.20B, the 1041st largest of 3,117 United States companies the cockpit tracks. Shares closed at $154.19 on 6 Nov 2026.
Performance Over six months the shares fell 0.5%, against -4.5% for the median peer and -1.1% for the United States market (cap-weighted) — 9th highest of 20 in its peer set.
Capital Return on invested capital runs 25.2 points below its cost of capital (6.4% WACC).
Next results Next results expected around 17 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $0 | -$464,000 | -$449,000 | -$399,000 | -$198,000 |
| EBITDA | n/a | -$83.7M | -$39.5M | -$31.3M | -$12.6M |
| Net income | -$102M | -$77.6M | -$36.1M | -$31.6M | -$12.6M |
| Free cash flow | n/a | -$37.1M | -$29.4M | -$29.9M | -$11.9M |
| Capital expenditure | n/a | $71,000 | $151,000 | $63,000 | $394,000 |
| Total debt | n/a | $429,000 | $537,000 | $886,000 | $866,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Belite Bio, Inc. ADR BLTE | $6.20B | 0% | n/a | n/a | n/a | n/a |
| Ionis Pharmaceuticals IONS | $6.55B | -48% | -7% | -68% | 7.7× | n/a |
| Astellas Pharma 4503.T | $28.2B | +11% | +19% | 23% | 1.9× | -11.0% |
| Annexon ANNX | $796M | -26% | n/a | n/a | n/a | n/a |
| Ocugen OCGN | $314M | -39% | -11% | -1,444% | 66.5× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BLTE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.1% | +2.0% | 10th lowest of 21 |
| 6-month return | -0.5% | -4.5% | 9th highest of 20 |
| Distance from 52-week high | -22.9% | -14.8% | 9th lowest of 21 |
| ROIC minus cost of capital | -25.2 pp | +1.5 pp | 4th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Belite Bio, Inc. ADR BLTE | United States | $6.20B | 0% | n/a | n/a | n/a | n/a | n/a |
| Ligand Pharmaceuticals LGND | United States | $6.12B | +38% | +1% | 14% | 26.9× | 57.8% | +7.5% |
| Biocon BIOCON.NS | India | $6.28B | -4% | +6% | 8% | 4.3× | n/a | n/a |
| Mirum Pharmaceuticals MIRM | United States | $6.12B | -13% | +42% | -21% | 9.7× | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.39B | -36% | n/a | -25% | 34.5× | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $6.40B | +21% | +14% | 20% | 8.8× | n/a | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.48B | 0% | +4% | 14% | 1.9× | -6.3% | +18.4% |
| Abbott India ABBOTINDIA.NS | India | $5.93B | -1% | +6% | 28% | 8.0× | 11.4% | +10.0% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.90B | -6% | +39% | 47% | 5.4× | 1.8% | +519.6% |
| Ionis Pharmaceuticals IONS | United States | $6.55B | -48% | -7% | -68% | 7.7× | n/a | n/a |
| Veradermics MANE | United States | $5.80B | +31% | n/a | n/a | n/a | n/a | n/a |
| Alkem Laboratories ALKEM.NS | India | $6.67B | -5% | +13% | 17% | 4.2× | 24.3% | +10.7% |
| Oruka Therapeutics ORKA | United States | $6.81B | +59% | n/a | n/a | n/a | n/a | n/a |
| Apotex Health APTX.TO | Canada | $5.62B | n/a | +4% | 32% | 3.0× | -13.5% | +4.2% |
| RemeGen 688331.SS | China | $6.90B | -26% | +272% | 61% | 4.9× | 2.8% | +303.3% |
| Gland Pharma GLAND.NS | India | $5.53B | +69% | +18% | 20% | 7.8× | 28.0% | +13.3% |
| ONO Pharmaceutical 4528.T | Japan | $7.01B | +2% | -2% | 22% | 2.0× | -8.2% | +10.8% |
| Amneal Pharmaceuticals AMRX | United States | $7.01B | +53% | +9% | 17% | 3.2× | 15.2% | +8.7% |
| PTC Therapeutics PTCT | United States | $5.47B | -11% | -35% | 22% | 3.4× | 8.0% | +35.4% |
| Supernus Pharmaceuticals SUPN | United States | $5.43B | -49% | +16% | 45% | 4.1× | 4.2% | +13.9% |
| Huadong Medicine 000963.SZ | China | $7.29B | -17% | +2% | 9% | 1.1× | -2.7% | +5.3% |